Intellia Therapeutics is trading 5% up at $11.47 as technical buying triggers a rebound following a sharp multi-day selloff that left shares in oversold territory.
- The move appears driven by bargain hunting and broader risk-on equity sentiment rather than any new company-specific catalysts.
- Intellia's gain stands in contrast to the broader biotech sector, with the SPDR S&P Biotech ETF (XBI) trading down more than 2% today.